{"id":808199,"date":"2026-03-06T15:59:11","date_gmt":"2026-03-06T15:59:11","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/808199\/"},"modified":"2026-03-06T15:59:11","modified_gmt":"2026-03-06T15:59:11","slug":"ozempic-style-glp-1-drugs-could-slash-complication-risks-after-heart-attacks-research-suggests","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/808199\/","title":{"rendered":"Ozempic-style GLP-1 drugs could slash complication risks after heart attacks, research suggests"},"content":{"rendered":"

A popular class of\u00a0weight-loss drugs<\/a>\u00a0may prevent life-threatening cardiac complications by opening microscopic blood vessels that often remain blocked after a heart attack, according to a study published this week in Nature Communications.<\/p>\n

The research, led by the University of Bristol and University College London, identified a biological brain-gut-heart signaling pathway.\u00a0<\/p>\n

This discovery appears to explain how GLP-1 drugs \u2014 which mimic glucagon-like peptide-1, a hormone that helps regulate blood sugar and appetite \u2014 protect heart tissue from a condition known as \u201cno-reflow.\u201d<\/p>\n

In nearly half of all heart attack patients, tiny capillaries (blood vessels) remain narrowed even after the main blocked artery is cleared. Pixel-Shot \u2013 stock.adobe.com<\/p>\n

\u201cIn nearly half of all heart attack patients, tiny blood vessels within the heart muscle remain narrowed, even after the main artery is cleared during\u00a0emergency medical treatment<\/a>,\u201d Dr. Svetlana Mastitskaya, the study\u2019s lead author and a senior lecturer at Bristol Medical School, said in a press release.<\/p>\n

\u201cThis results in a complication known as \u2018no-reflow,\u2019 where blood is unable to reach certain parts of the heart tissue.\u201d<\/p>\n

This lack of blood flow increases the risk of heart failure and death within a year.\u00a0GLP-1 medications\u00a0could prevent this, according to the researchers.<\/p>\n

How it works<\/p>\n

When the GLP-1 hormone is released in the gut or administered as a drug, it sends a signal\u00a0to the brain, which then sends a signal to the heart that switches on special potassium channels in tiny cells called pericytes.<\/p>\n

The findings suggest that existing GLP-1 medications, already used for type 2 diabetes and obesity, could be repurposed as emergency treatments. Fernanda \u2013 stock.adobe.com<\/p>\n

When these channels open, the pericytes relax, which allows the small blood vessels (capillaries) to widen and improve blood flow to the heart muscle, the researchers noted.<\/p>\n

The new study used animal models and cellular imaging to track how GLP-1 interacts with heart tissue. When the researchers removed the potassium channels, the drugs no longer protected the heart \u2014 confirming they play a key role.<\/p>\n

The findings suggest that existing\u00a0GLP-1 medications, already used for type 2 diabetes and obesity, could be repurposed as emergency treatments during or immediately after a heart attack to reduce tissue damage.<\/p>\n

This lack of blood flow increases the risk of heart failure and death within a year.\u00a0GLP-1 medications\u00a0could prevent this, according to the researchers. \u00c3\u00c5\u00c3\u00c2\u00b0\u00c3\u00e2\u00ac\u00c3\u00c2\u00b8\u00c3\u00c2\u00bd\u00c3\u00c2\u00b0 \u00c3\u00e2\u00c3\u00c2\u00b5\u00c3\u00c2\u00bc\u00c3\u00c2\u00b5\u00c3\u00cb\u00c3\u00c2\u00ba\u00c3\u00c2\u00be \u2013 stock.adobe.com<\/p>\n

The researchers noted several limitations, including that the study relied on animal models.<\/p>\n

Clinical trials are necessary to determine whether the brain-gut-heart pathway operates with the same timing and efficacy in humans.<\/p>\n

Additionally, while the study highlights the drug\u2019s immediate benefits during a heart attack, it does not establish whether long-term use of the medication provides a pre-existing\u00a0level of protection.<\/p>\n

The research was primarily funded by the British Heart Foundation.<\/p>\n","protected":false},"excerpt":{"rendered":"A popular class of\u00a0weight-loss drugs\u00a0may prevent life-threatening cardiac complications by opening microscopic blood vessels that often remain blocked…\n","protected":false},"author":2,"featured_media":808200,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[535,105,302,4326,370,1093,16,15,734],"class_list":{"0":"post-808199","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-drugs","9":"tag-health","10":"tag-heart-disease","11":"tag-medication","12":"tag-ozempic","13":"tag-public-health","14":"tag-uk","15":"tag-united-kingdom","16":"tag-weight-loss"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/116183064027884520","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/808199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=808199"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/808199\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/808200"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=808199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=808199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=808199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}